Is Lenvatinib on the market?

In February 2015, the U.S. Food and Drug Administration (FDA) approved Lenvatinib for the treatment of progressive, radioactive iodine-refractory differentiated thyroid cancer. In May of the same year, the European Medicines Agency (EMA) approved the drug for the same indication, and its trade name is Lenvima. In May 2016, the FDA approved it (in combination with everolimus) for the treatment of advanced renal cell carcinoma after an anti-angiogenic treatment.

In August 2018, the FDA approved it for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). In September 2019, the FDA approved its combination with pembrolizumab to treat patients with certain types of endometrial cancer. Regarding safety, most side effects of lenvatinib can be adequately controlled through dose reduction or temporary interruption of treatment; there are no unexpected safety concerns when used with pembrolizumab. Lenvatinib The original drug was approved by the State Food and Drug Administration in 2018 and has been launched in China. The generic name is lenvatinib mesylate capsules and the trade name is Lenvima, and it is covered by Class B medical insurance.

Lenvatinib original drug specification 4mg*30 tablets per box listed in China may cost more than 3,000 yuan per box. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).